Virology, epidemiology, transmissions, diagnostic tests, prophylaxis and treatments of human Mpox: Saudi Arabia perspective.

Almonther Abdullah Hershan
Author Information
  1. Almonther Abdullah Hershan: Department of Basic Medical Sciences, College of Medicine, The University of Jeddah, Jeddah, Saudi Arabia.

Abstract

Mpox (Monkeypox) is a highly contagious viral disease that can be transmitted from animal-to-human or human-to-human through intimate contact, Mpox is caused by the monkeypox virus (MPXV), which is an enveloped double-stranded DNA that belongs to the genus family, and subfamily Mpox cases were previously only reported in West and Central Africa, however in recent times non-endemic countries including Saudi Arabia (SA) also reported confirmed Mpox cases. The first laboratory-confirmed human Mpox case in SA was reported on 14 July 2022, since then a number of confirmed Mpox cases have been reported by WHO in SA. These confirmed Mpox cases in SA were observed among individuals with a history of visiting European Union countries. SA is not only at risk of importation of Mpox cases owing to travel to such countries, but also there are various other risk factors including geographic proximity to the African continent, trade in exotic animals, and massive inflow of tourists. Therefore, government health authorities of SA should continue to collaborate with various international health organizations including WHO to prevent, manage or monitor potential health risks at most of the entry points in SA including highways, seaports, and airports by ensuring adherence to hygiene protocols, vaccinations, and health screenings. There are a range of diagnostic tests are currently available that can be used in SA to confirm Mpox infections, including real-time PCR, loop-mediated isothermal amplification, serological testing, clustered regularly interspaced short palindromic repeat-CRISPR-associated protein (CRISPR-Cas)-based systems, whole-genome sequencing, electron microscopy, and virus isolation and culture. There is no approved treatment specifically for Mpox, however multiple approved antiviral agents for smallpox treatment were found to be useful in Mpox treatment and in the management of Mpox outbreaks, such as- trifluridine, brincidofovir, tecovirimat, and cidofovir. The aim of this review is to provide valuable insights regarding virology, pathogenesis, epidemiology, transmissions, clinical presentation, diagnostic tests, prophylactic measures and therapeutic options of Mpox from SA perspective. Moreover, a side-by-side discussion on the global trend and scenarios of Mpox has been provided for comparison and further improvement in measures against Mpox in SA.

Keywords

References

  1. PLOS Glob Public Health. 2024 Jan 18;4(1):e0002731 [PMID: 38236835]
  2. MMWR Morb Mortal Wkly Rep. 2022 Oct 07;71(40):1278-1282 [PMID: 36201401]
  3. J Travel Med. 2023 Dec 28;30(8): [PMID: 38006358]
  4. Viruses. 2010 Oct;2(10):2381-2403 [PMID: 21197387]
  5. Am J Clin Dermatol. 2023 Jul;24(4):541-556 [PMID: 37106278]
  6. Int J Environ Res Public Health. 2022 Nov 24;19(23): [PMID: 36497712]
  7. Emerg Microbes Infect. 2024 Dec;13(1):2387442 [PMID: 39082272]
  8. Signal Transduct Target Ther. 2022 Nov 2;7(1):373 [PMID: 36319633]
  9. Trends Microbiol. 2012 Feb;20(2):80-7 [PMID: 22239910]
  10. ACS Infect Dis. 2020 Sep 11;6(9):2319-2336 [PMID: 32786280]
  11. Life (Basel). 2023 Sep 26;13(10): [PMID: 37895350]
  12. Future Virol. 2013 Feb 1;8(2):129-157 [PMID: 23626656]
  13. Molecules. 2023 Jan 09;28(2): [PMID: 36677717]
  14. BMC Biol. 2020 Oct 28;18(1):153 [PMID: 33115440]
  15. J Med Virol. 2023 Jan;95(1):e28218 [PMID: 36229902]
  16. Vector Borne Zoonotic Dis. 2012 May;12(5):400-9 [PMID: 22217169]
  17. Travel Med Infect Dis. 2023 Mar-Apr;52:102550 [PMID: 36754340]
  18. Travel Med Infect Dis. 2024 Mar-Apr;58:102694 [PMID: 38336336]
  19. Open Forum Infect Dis. 2022 Jun 23;9(7):ofac310 [PMID: 35891689]
  20. Int J STD AIDS. 2025 Jan;36(1):83-85 [PMID: 39325090]
  21. Nat Biotechnol. 2020 Jul;38(7):870-874 [PMID: 32300245]
  22. Int J Surg. 2022 Aug;104:106745 [PMID: 35777695]
  23. Cureus. 2024 Apr 23;16(4):e58866 [PMID: 38800170]
  24. Science. 2018 Apr 27;360(6387):439-444 [PMID: 29449508]
  25. Lancet. 2022 Aug 27;400(10353):661-669 [PMID: 35952705]
  26. Int J Surg. 2022 Sep;105:106873 [PMID: 36055631]
  27. Clin Infect Dis. 2023 Jan 6;76(1):155-164 [PMID: 35904001]
  28. JAMA. 2022 Sep 13;328(10):921-922 [PMID: 35951336]
  29. Nat Rev Immunol. 2022 Oct;22(10):597-613 [PMID: 36064780]
  30. Infect Dis Rep. 2022 Nov 14;14(6):855-883 [PMID: 36412745]
  31. J Clin Med. 2024 Apr 12;13(8): [PMID: 38673507]
  32. BMJ. 2022 Jul 28;378:e072410 [PMID: 35902115]
  33. J Comp Pathol. 2013 Jan;148(1):6-21 [PMID: 22884034]
  34. Virol J. 2010 May 28;7:110 [PMID: 20509894]
  35. Emerg Infect Dis. 2023 May;29(5):997-1001 [PMID: 36856759]
  36. New Microbiol. 2005 Jan;28(1):1-12 [PMID: 15782621]
  37. J Infect Chemother. 2023 Feb;29(2):228-231 [PMID: 36283609]
  38. Lancet Microbe. 2023 Oct;4(10):e800-e810 [PMID: 37722405]
  39. New Microbes New Infect. 2023 Mar;52:101108 [PMID: 36855600]
  40. PLoS Pathog. 2015 Jul 02;11(7):e1004904 [PMID: 26135739]
  41. iScience. 2023 Jun 16;26(6):106759 [PMID: 37206155]
  42. Lancet. 2022 Oct 29;400(10362):1509 [PMID: 36522201]
  43. Vaccines (Basel). 2022 Aug 18;10(8): [PMID: 36016230]
  44. Vaccines (Basel). 2023 Feb 21;11(3): [PMID: 36992085]
  45. PLoS Negl Trop Dis. 2022 Feb 11;16(2):e0010141 [PMID: 35148313]
  46. Int Immunopharmacol. 2022 Dec;113(Pt A):109382 [PMID: 36330915]
  47. Expert Rev Anti Infect Ther. 2021 Mar;19(3):331-344 [PMID: 32882158]
  48. Saudi J Biol Sci. 2024 Jul;31(7):104023 [PMID: 38799719]
  49. Vaccines (Basel). 2022 Nov 21;10(11): [PMID: 36423066]
  50. Nat Biomed Eng. 2021 Jul;5(7):643-656 [PMID: 34272525]
  51. MMWR Morb Mortal Wkly Rep. 2022 Aug 12;71(32):1018-1022 [PMID: 35951487]
  52. MMWR Morb Mortal Wkly Rep. 2022 Sep 16;71(37):1190-1195 [PMID: 36107794]
  53. Emerg Microbes Infect. 2022 Dec;11(1):2600-2631 [PMID: 36263798]
  54. Am J Ophthalmol Case Rep. 2023 Mar;29:101779 [PMID: 36573234]
  55. BMJ. 2022 Aug 23;378:o2080 [PMID: 35998923]
  56. Lancet Microbe. 2023 Jan;4(1):e15-e16 [PMID: 36209756]
  57. IJID Reg. 2024 Mar 21;11:100358 [PMID: 38590626]
  58. Emerg Infect Dis. 2019 May;25(5):980-983 [PMID: 30848724]
  59. Viruses. 2024 Jan 04;16(1): [PMID: 38257783]
  60. Sci Rep. 2020 Nov 09;10(1):19307 [PMID: 33168908]
  61. mSphere. 2021 Feb 3;6(1): [PMID: 33536322]
  62. Euro Surveill. 2022 Jun;27(24): [PMID: 35713026]
  63. Travel Med Infect Dis. 2022 Nov-Dec;50:102459 [PMID: 36109000]
  64. Signal Transduct Target Ther. 2023 Dec 27;8(1):458 [PMID: 38148355]
  65. New Microbes New Infect. 2022 Nov 15;49-50:101049 [PMID: 36407851]
  66. Viruses. 2023 Apr 18;15(4): [PMID: 37112975]
  67. Lancet Infect Dis. 2023 Apr;23(4):445-453 [PMID: 36521505]
  68. Virol J. 2012 Jan 06;9:5 [PMID: 22225589]
  69. Infect Med (Beijing). 2023 Nov 05;2(4):262-272 [PMID: 38205182]
  70. JAMA. 2024 Nov 19;332(19):1652-1662 [PMID: 39401235]
  71. Lancet Microbe. 2023 Apr;4(4):e209 [PMID: 36563704]
  72. Cell. 2016 Oct 20;167(3):684-694.e9 [PMID: 27768891]
  73. J Infect Public Health. 2023 Apr;16(4):531-541 [PMID: 36801633]
  74. Lancet. 2023 Jan 7;401(10370):60-74 [PMID: 36403582]
  75. Front Pharmacol. 2023 May 05;14:1149909 [PMID: 37214444]
  76. Viruses. 2023 Apr 10;15(4): [PMID: 37112916]
  77. Sci Rep. 2021 Feb 18;11(1):4111 [PMID: 33602985]
  78. Ann Med Surg (Lond). 2022 Sep 17;82:104686 [PMID: 36160299]
  79. Emerg Infect Dis. 2022 Nov;28(11):2336-2338 [PMID: 36104166]
  80. Sci Adv. 2021 Aug 6;7(32): [PMID: 34362739]
  81. Front Public Health. 2023 Nov 08;11:1254545 [PMID: 38026424]
  82. Vaccines (Basel). 2022 Dec 08;10(12): [PMID: 36560508]
  83. N Engl J Med. 2022 Nov 10;387(19):1783-1793 [PMID: 36286263]
  84. Lab Invest. 2004 Sep;84(9):1200-8 [PMID: 15208646]
  85. Lancet Neurol. 2022 Oct;21(10):872 [PMID: 36115356]
  86. Science. 2017 Apr 28;356(6336):438-442 [PMID: 28408723]
  87. Vaccines (Basel). 2022 Sep 15;10(9): [PMID: 36146612]
  88. N Engl J Med. 2004 Jan 22;350(4):342-50 [PMID: 14736926]
  89. JAMA. 2022 Jul 12;328(2):139-140 [PMID: 35696257]
  90. Int J Surg. 2022 Aug;104:106774 [PMID: 35863624]
  91. Biosaf Health. 2022 Dec;4(6):376-385 [PMID: 36406058]
  92. New Microbes New Infect. 2024 Sep 24;62:101487 [PMID: 39429728]
  93. Transplantation. 2022 Nov 1;106(11):e512-e513 [PMID: 35973036]
  94. Lancet Microbe. 2023 Apr;4(4):e277-e283 [PMID: 36898398]
  95. Vaccines (Basel). 2022 Dec 07;10(12): [PMID: 36560502]
  96. Viruses. 2019 Dec 23;12(1): [PMID: 31877989]
  97. Lancet. 2022 Dec 3;400(10367):1953-1965 [PMID: 36403584]
  98. Int J Surg. 2022 Aug;104:106812 [PMID: 35944803]
  99. Health Sci Rep. 2022 Aug 23;5(5):e798 [PMID: 36032515]
  100. Cureus. 2022 Aug 26;14(8):e28441 [PMID: 36176858]
  101. Vaccines (Basel). 2022 Aug 28;10(9): [PMID: 36146486]
  102. Sci Rep. 2019 Mar 14;9(1):4494 [PMID: 30872672]
  103. Cell Rep Methods. 2023 Oct 23;3(10):100620 [PMID: 37848032]
  104. Int J Mol Sci. 2022 Jul 17;23(14): [PMID: 35887214]
  105. Rev Med Virol. 2024 May;34(3):e2541 [PMID: 38743385]
  106. J Virol Methods. 2011 Aug;175(2):163-9 [PMID: 21635922]
  107. Travel Med Infect Dis. 2022 Sep-Oct;49:102392 [PMID: 35752293]
  108. J Infect Public Health. 2023 Mar;16(3):341-345 [PMID: 36680849]
  109. Biomed Pharmacother. 2023 Nov;167:115597 [PMID: 37783148]
  110. Expert Rev Anti Infect Ther. 2022 Oct;20(10):1249-1252 [PMID: 35953443]
  111. MMWR Morb Mortal Wkly Rep. 2022 Oct 21;71(42):1343-1347 [PMID: 36264836]

MeSH Term

Humans
Saudi Arabia
Animals
Mpox, Monkeypox
Monkeypox virus
Diagnostic Tests, Routine
Antiviral Agents

Chemicals

Antiviral Agents

Word Cloud

Created with Highcharts 10.0.0MpoxSAcasesincludingreportedhealthcountriesSaudiArabiaconfirmeddiagnosticteststreatmentcanvirushoweveralsohumanWHOriskvariousapprovedvirologyepidemiologytransmissionsmeasuresperspectiveprophylaxisMonkeypoxhighlycontagiousviraldiseasetransmittedanimal-to-humanhuman-to-humanintimatecontactcausedmonkeypoxMPXVenvelopeddouble-strandedDNAbelongsgenusfamilysubfamilypreviouslyWestCentralAfricarecenttimesnon-endemicfirstlaboratory-confirmedcase14July2022sincenumberobservedamongindividualshistoryvisitingEuropeanUnionimportationowingtravelfactorsgeographicproximityAfricancontinenttradeexoticanimalsmassiveinflowtouristsThereforegovernmentauthoritiescontinuecollaborateinternationalorganizationspreventmanagemonitorpotentialrisksentrypointshighwaysseaportsairportsensuringadherencehygieneprotocolsvaccinationsscreeningsrangecurrentlyavailableusedconfirminfectionsreal-timePCRloop-mediatedisothermalamplificationserologicaltestingclusteredregularlyinterspacedshortpalindromicrepeat-CRISPR-associatedproteinCRISPR-Cas-basedsystemswhole-genomesequencingelectronmicroscopyisolationculturespecificallymultipleantiviralagentssmallpoxfoundusefulmanagementoutbreaksas-trifluridinebrincidofovirtecovirimatcidofoviraimreviewprovidevaluableinsightsregardingpathogenesisclinicalpresentationprophylactictherapeuticoptionsMoreoverside-by-sidediscussionglobaltrendscenariosprovidedcomparisonimprovementVirologytreatmentsMpox:therapeuticsvaccines

Similar Articles

Cited By